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INTRODUCTION
The introduction of biological agents that counter tumor
necrosis factor (TNF)- represents a major advance in the
treatment of rheumatoid arthritis (RA) and other systemic
inflammatory diseases, including ankylosing spondylitis (AS)
(1-4). However, the association with increased occurrence of
tuberculosis is a major concern (5, 6). TNF- is an essential
cytokine that plays an important role in the immune res-
ponse against Mycobacterium tuberculosis (7), and the reemer-
gence of active tuberculosis has been reported soon after
patients began taking TNF- antagonists (8). Therefore, it
is critical to diagnose and treat latent tuberculosis infection
(LTBI) before commencing treatment with TNF- antago-
nists in these patients. 
Isoniazid has been the mainstay of LTBI treatment for over
40 yr worldwide. Unfortunately, the recommended lengthy
treatment (9 months) with isoniazid has compromised this
regimen as an effective tool, as only 50-60% complete the
regimen (9). In the United States, 6 months of isoniazid
(6H), 4 months of rifampin (4R), and 2 months of rifampin
and pyrazinamide (2RZ) are recommended as acceptable
alternatives to the preferred 9 months of isoniazid (9H) (9).
After these recommendations were published in 2000, they
were revised to indicate that 2RZ should not be generally
offered because it caused severe hepatotoxicity and mortali-
ty (10). In the United Kingdom, 6H and 3 months of iso-
niazid and rifampin (3HR) are recommended (11). 
In December 2004, the Korea Food and Drug Administra-
tion strongly recommended treating LTBI in patients before
starting TNF- antagonist therapy using one of the recom-
mended regimens: 6H (or 9H), 4R, 3HR, or 2RZ (12). In
addition to the low completion rate due to the lengthy treat-
ment, the 6H and 9H regimens have limitations in coun-
tries with high isoniazid resistance rates. A recent national
survey found that 9.9% of new tuberculosis cases in Korea
Jong Wook Yun, Seong Yong Lim
1, 
Gee Young Suh, Man Pyo Chung,
Hojoong Kim, O Jung Kwon,
Hoon-Suk Cha*, Eun-Mi Koh*,
Won-Jung Koh
Division of Pulmonary and Critical Care Medicine and
Rheumatology*, Department of Medicine, Samsung
Medical Center, Sungkyunkwan University School of
Medicine, Seoul, Korea
Jong Wook Yun and Seong Yong Lim contributed
equally to this work.
1Present address: Division of Pulmonary and Critical
Care Medicine, Department of Internal Medicine,
Kangbuk Samsung Hospital, Sungkyunkwan 
University School of Medicine, Seoul, Korea
Address for correspondence
Won-Jung Koh, M.D.
Division of Pulmonary and Critical Care Medicine,
Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, 50
Irwon-dong, Gangnam-gu, Seoul 135-710, Korea
Tel : +82.2-3410-3429, Fax : +82.2-3410-6542
E-mail : wjkoh@skku.edu
*This work was supported by the Samsung Biomedical
Research Institute grant (# SBRI C-A6-402-1). 
779
J Korean Med Sci 2007; 22: 779-83
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Diagnosis and Treatment of Latent Tuberculosis Infection in Arthritis
Patients Treated with Tumor Necrosis Factor Antagonists in Korea
Tumor necrosis factor (TNF) is essential for host defense against Mycobacterium
tuberculosis, and the risk of reactivation of latent tuberculosis infection (LTBI) increas-
es with anti-TNF therapy. This study estimated the prevalence of LTBI and evalu-
ated the safety and completion rate of short-course therapy with isoniazid plus
rifampin for 3 months to treat LTBI in a cohort of Korean arthritis patients before
initiating anti-TNF therapy. We retrospectively studied the files of 112 consecutive
patients to evaluate LTBI before starting anti-TNF drugs. Screening tests were
performed, including a tuberculin skin test and chest radiography. LTBI treatment
was indicated in 41 patients (37%). Of these, three patients refused the LTBI treat-
ment. Of the 38 patients who underwent LTBI treatment, 36 (95%) took isoniazid
plus rifampin for 3 months. Six patients (16%) showed transient elevations of liver
enzymes during the LTBI treatment. Overall, 35 patients (92%) completed the LTBI
treatment as planned. In conclusion, LTBI was diagnosed in one-third of Korean
arthritis patients before initiating anti-TNF therapy. A high percentage of these pa-
tients completed 3 months of LTBI treatment with isoniazid plus rifampin without
serious complications.
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involved isoniazid-resistant strains (13). Although the regi-
men of 3HR or 4R has some merits in this situation, the
efficacy of each regimen for treating LTBI has never been
evaluated in Korea.
Therefore, this study estimated the prevalence of LTBI and
evaluated the safety and completion rate of the 3HR regimen
for treating LTBI in a cohort of Korean arthritis patients
before commencing anti-TNF agents. 
MATERIALS AND METHODS 
Patients 
We retrospectively studied the files of 112 consecutive
patients with RA or AS who visited our facility to evaluate
LTBI before starting anti-TNF drugs during a 22-month
period (December 2004-September 2006) at the Samsung
Medical Center, Seoul, Korea. Diagnosis of RA or AS was
defined according to the proposed criteria (14, 15). All the
patients were diagnosed, treated, and followed in the same
rheumatology center. Approval from the institutional review
board was obtained to review the patient records retrospec-
tively and to publish the results.
Diagnosis of LTBI
The diagnosis of LTBI was made from the medical histo-
ry and screening tests. The evaluation of the medical history
included current symptoms, a prior history of treatment for
tuberculosis, and a recent contact history of patient with active
pulmonary tuberculosis. All the patients had a tuberculin
skin test (TST) and posteroanterior chest radiography (CXR)
taken before beginning the anti-TNF treatment. Patients
with a history of adequate previous therapy for tuberculosis
and no current evidence of active pulmonary tuberculosis on
CXR were not given the TST. 
The TST was performed on the volar side of the forearm
according to the Mantoux method (9) using a 2-TU dose of
purified protein derivative RT23 (Statens Serum Institute,
Copenhagen, Denmark). The TST was considered positive
when the transverse diameter of the induration exceeded 10
mm after 48-72 hr using the ball-point method (16). A posi-
tive TST result without an active tuberculosis lesion on CXR
was considered an indication for LTBI treatment.
In addition, a recent contact with patients having active
pulmonary tuberculosis, an abnormal CXR suggesting latent
tuberculosis without adequate prior treatment, or an inade-
quate treatment history of tuberculosis were indications for
LTBI treatment regardless of the TST results (12). When
LTBI treatment was indicated, the anti-TNF treatment was
started 1 month later. All the patients received etanercept.
Treatment and monitoring
All patients who were diagnosed with LTBI had their liver
chemistry, hepatitis B virus surface antigen, and hepatitis C
virus antibody assessed before commencing LTBI treatment,
and none of these patients had abnormal liver chemistry or
were positive for hepatitis B virus surface antigen or hepati-
tis C virus antibody. In the LTBI treatment, most of the pa-
tients were placed on the 3HR regimen (isoniazid 300 mg/
day plus rifampin 600 mg/day, if the body weight was <50
kg, rifampin 450 mg/day for 3 months). A few patients were
placed on the 4R regimen (rifampin, dose as above for 4
months). 
The attending physician assessed adherence and adverse
reactions using the clinical signs, symptoms, and liver chem-
istry at 4-week intervals. The serum aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) levels were
monitored monthly. The following criteria were used to de-
fine transient transaminase elevation and drug-induced hep-
atotoxicity (17). Transient transaminase elevation was diag-
nosed if the AST/ALT levels increased, but were still less
than three times the upper normal limit (120 IU/L), and
resolved spontaneously despite continued medication. Drug-
induced hepatotoxicity was diagnosed when liver transami-
nase levels exceeded 120 IU/L.
Data analysis
Numerical variables were given as the mean±standard
deviation (SD). Categorical variables were presented as num-
bers and percentages. Variables were compared between
patients with AS and RA using the Fisher’s exact test, chi-
square test, and Student’s t-test, as appropriate. A p<0.05
was considered statistically significant.
RESULTS
Patients characteristics
The study identified 112 consecutive patients referred for
the evaluation of LTBI before starting anti-TNF therapy (71
men and 41 women; mean age±SD, 41±15 yr). The diagno-
sis of RA was established in 41 patients (37%) and AS in 71
(63%). The patient characteristics are summarized in Table 1. 
Diagnosis of LTBI
No patient had signs, symptoms, or CXR findings sug-
gestive of current active pulmonary tuberculosis. The TST
was performed in 106 patients, excluding the six patients
who had received adequate therapy for previous tuberculo-
sis. Forty-one patients had a positive TST. Of the patients
with a negative TST, none had recent contact with patientsTNF- Antagonist Treatment and Latent Tuberculosis Infection in Korea 781
with active pulmonary tuberculosis, an abnormal CXR sug-
gesting latent tuberculosis, or inadequately treated prior
tuberculosis. Therefore, LTBI treatment was indicated in 41
arthritis patients (37%) scheduled to receive anti-TNF agents.
The prevalence of LTBI and the clinical characteristics of
the patients with RA and AS differed. LTBI was diagnosed
in more patients with AS (35/71, 49%) than with RA (6/41,
15%; p<0.001). Most of the patients with AS were men (64
[90%] of 71), while few men had RA (7 [17%] of 41; p<
0.001]. The patients with AS were younger (mean age 34
yr) than those with RA (mean age 53 yr; p<0.001). Patients
with AS were more likely to have a Bacillus Calmette-Guerin
(BCG) scar (57 [80%]of 71) compared to those with RA (23
[56%] of 41; p=0.003). The percentage of patients receiving
immunosuppressants, including systemic glucocorticoids or
methotrexate, was higher in patients with RA compared to
those with AS (p<0.001; Table 2).
Treatment of LTBI
Three of the 41 patients who were diagnosed with LTBI
refused both LTBI treatment and anti-TNF drug therapy.
Therefore, 38 patients received LTBI treatment; 3HR in 36
patients (95%) and 4R in two patients (5%). 
Six patients (16%, 6/38) showed a transient elevation of
AST or ALT during the LTBI treatment, which normalized
spontaneously without discontinuing the treatment. The
AST and ALT levels in these patients are shown in Table 3.
Three patients (8%, 3/38) were switched to another regimen
because of adverse reactions, such as a skin rash or gastroin-
testinal disturbance. Two patients starting the 3HR regimen
were switched to the 4R regimen and one patient starting
with the 4R regimen was switched to the 6H regimen. Thir-
ty-five patients (92%, 35/38) completed the LTBI treatment
as planned, while three were nonadherent. 
DISCUSSION
The main objectives of this study were to estimate the
prevalence of LTBI and to evaluate the completion rate and
safety of the 3HR regimen for treating LTBI in Korean pa-
tients with RA or AS before starting anti-TNF agents. Using
the TST, LTBI was diagnosed in more than one-third in these
patients and the treatment of LTBI with the 3HR regimen
had a high completion rate with few complications. 
Since TNF- plays a central role in mycobacterial infec-
tion, it is not surprising that anti-TNF therapy is associated
with the progression of recently acquired tuberculosis or the
reactivation of LTBI. Currently, three anti-TNF agents are
in clinical use: etanercept, infliximab, and adalimumab. As
of June 2002, 295 cases of tuberculosis among patients receiv-
ing infliximab and 36 cases among those receiving etaner-
cept had been reported to the US Food and Drug Adminis-
tration (18). Adalimumab was also associated with tubercu-
losis during clinical trials (6). Most patients were thought
Patient characteristic Value
Age in yr (mean±SD) 43±15
Sex 
Male 71 (63%)
Female 41 (37%)
Underlying disease
Rheumatoid arthritis 41 (37%)
Ankylosing spondylitis 71 (63%)
History of tuberculosis with adequate treatment 6 (5%)
BCG scar
Yes 80 (71%)
No 19 (17%)
N/A 13 (12%)
Current active tuberculosis 0
Latent tuberculosis infection 41 (37%)
Table 1. The characteristics of the 112 patients with rheuma-
toid arthritis or ankylosing spondylitis before initiating anti-TNF
therapy
Characteristics
Rheumatoid
arthritis
(n=41)
Ankylosing
spondylitis
(n=71)
p
value
Age in yr (mean±SD) 53±14 34±11 <0.001
Sex
Male 7 (17%) 64 (90%) <0.001
Female 34 (83%) 7 (10%)
History of tuberculosis 3 (7%) 3 (4%) 0.667
BCG scar
Yes 23 (56%) 57 (80%) 0.003
No 13 (32%) 6 (8%)
N/A 5 (12%) 8 (11%)
Immunosuppressants
Glucocorticoids 28 (68%) 20 (28%) <0.001
Methotrexate 34 (83%) 35 (49%) 0.001
Latent tuberculosis infection 6 (15%) 35 (49%) <0.001
Table 2. Comparison of patient characteristics between those
with rheumatoid arthritis and those with ankylosing spondylitis
AST, aspartate aminotransferase; ALT, alanine aminotransferase; LTBI,
latent tuberculosis infection; M, male; F, female; 3HR, isoniazid plus
rifampin for 3 months; 4R, rifampin for 4 months.
Sex/Age (yr) Regimen Onset of elevation
(weeks)
Peak AST/ALT 
levels
M/28 3HR 4 52/32
F/38 3HR 4 55/54
M/35 3HR 4 48/57
M/53 3HR 8 41/61
M/39 3HR 8 45/87
M/33 4R 4 47/93
Table 3. Drug-induced transient elevation of AST/ALT during
LTBI treatment
BCG, Bacillus Calmette-Guerin; N/A, not available. N/A, not available.782 J.W. Yun, S.Y. Lim, G.Y. Suh, et al.
to have a reactivation of LTBI. Tuberculosis associated with
anti-TNF agent therapy has an unusual presentation, as more
than half of the cases have extrapulmonary disease, while one-
fourth have disseminated disease (8). Therefore, all candidates
for anti-TNF therapy should undergo screening for LTBI
before initiating these drugs. In December 2004, the Korea
Food and Drug Administration strongly recommended that
LTBI be diagnosed and treated in patients before starting
TNF antagonists. 
The prevalence of LTBI in arthritis patients before initiat-
ing anti-TNF therapy has never been reported in Korea. In
this study, 37% (41/112) of the patients who were scheduled
to receive anti-TNF agents had a positive TST, and LTBI
treatment was indicated. 
We used the TST for the diagnosis of LTBI, but the TST
has several limitations. The interpretation of negative tests
is complicated by the effect of immunosuppressants preclud-
ing effective testing. Moreover, patients with RA might not
produce an adequate delayed type hypersensitivity reaction
to tuberculin because of their deficient cell-mediated immu-
nity (19, 20). Therefore, a false negative TST makes it unre-
liable for determining the risk of tuberculosis (21). In addi-
tion, it is still uncertain whether prior BCG vaccination
affects the interpretation of a TST. Individuals vaccinated
with BCG are more likely to have a positive TST; however,
the size of the reaction almost never exceeds 15 mm (22). In
this study, the prevalence of LTBI differed in patients with
RA (15%) and AS (49%). These results may have been in-
fluenced by confounding factors such as age, BCG vaccina-
tion status, and the use of immunosuppressant agents, includ-
ing systemic glucocorticoids. 
New blood tests, based on the detection of interferon-
produced by T cells in response to antigens specific to M.
tuberculosis, have recently been developed and are available
commercially (QuantiFERON-TB Gold; Cellestis Ltd; Vic-
toria, Australia and T-SPOT.TB assay; Oxford Immunotec;
Oxford, United Kingdom). These tests might be more accu-
rate than the tuberculin skin test (23, 24), but the number of
studies in immunosuppressed patients is limited. Therefore,
until other more accurate diagnostic tests are available for
identifying LTBI in routine clinical practice, the TST should
continue to be used. 
Four potential treatment regimens are used for LTBI: 6H,
4R, 3HR, or 2RZ (9, 11, 12). Rifampin and pyrazinamide
for 2 months (2RZ) had a very high rate of hepatitis with
several fatalities reported. Accordingly, the choice of regimen
is between 6H (or 9H), which has a lower hepatitis rate, and
3HR (or 4R), which may have advantages in terms of short-
er duration and possibly better adherence, and less risk of
drug resistance developing if active disease is present (11).
In particular, poor patient adherence to the 6H or 9H regi-
men due to the long course and a high prevalence of isoni-
azid-resistant tuberculosis in Korea make the 6H or 9H
regimens less advantageous for LTBI treatment.
A recent meta-analysis demonstrated that short-course ther-
apy with isoniazid plus rifampin for 3 months was equiva-
lent to standard therapy with isoniazid for 6-12 months in
terms of efficacy, the proportion of severe side effects, and
mortality (25). With due regard to these results, 3HR was
the main regimen used to treat LTBI in our institution,
shortly after the recommendation for the diagnosis, and
treatment of LTBI was released by Korea Food and Drug
Administration. 
In this study, most (95%, 36/38) of the patients in whom
LTBI treatment was indicated received daily short-course
therapy with isoniazid plus rifampin for 3 months. Only
two patients receiving the 3HR regimen were switched to
the 4R regimen due to drug side effects, including skin rash
or gastrointestinal disturbance. Five patients (14%, 5/36)
receiving 3HR experienced transient elevation of AST or
ALT during the LTBI treatment, which normalized sponta-
neously without discontinuing the treatment. Moreover, the
completion rate was relatively high in this study (92%, 35/
38), although our study population was small. 
In conclusion, the diagnosis of LTBI was made in slightly
more than one-third of Korean arthritis patients before insti-
tuting anti-TNF therapy. In these patients, 3 months with
isoniazid plus rifampin for LTBI treatment showed had a
high completion rate without serious complications.
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